Newsroom | 1638 results

Sorted by: Latest

Vitamins/Supplements
-

Jamieson Wellness Inc. Reports Fourth Quarter and Full Year 2025 Results

TORONTO--(BUSINESS WIRE)--Jamieson Wellness Inc. (“Jamieson Wellness” or the “Company”) (TSX: JWEL) today reported financial results for its fourth quarter and full year ended December 31, 2025. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS and other financial measures. See “Non-IFRS and Other Financial Measures” below. Management Commentary “2025 was an outstanding year for Jamieson Wellness, driven by sustained glo...
-

Jamieson Wellness Inc. Announces Renewal of Normal Course Issuer Bid

TORONTO--(BUSINESS WIRE)--Jamieson Wellness Inc. (“Jamieson Wellness” or the “Company”) (TSX: JWEL) announced today that it has received approval from the Toronto Stock Exchange (the “TSX”) to renew its normal course issuer bid (the “NCIB”) for the repurchase of common shares as appropriate opportunities arise from time to time in accordance with the requirements of the TSX. Pursuant to the NCIB, the Company may purchase for cancellation up to 3,444,429 common shares of the Company, which repre...
-

Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex Reference Standards business to LGC, as of February 24, 2026, in an all-cash transaction. The divestiture further streamlines Niagen Bioscience’s operations, advances the Company's strategy to exit non-core activities, and focuses resources on NAD+ science, intellectual prope...
-

The Beachbody Company, Inc. Announces Fourth Quarter 2025 Earnings Release Date, Conference Call, and Webcast

EL SEGUNDO, Calif.--(BUSINESS WIRE)--The Beachbody Company, Inc. (NASDAQ: BODI) (“BODi” or the “Company”), a leading fitness and nutrition company, will release its fourth quarter 2025 results on Tuesday, March 10, 2026, after the U.S. stock market closes. The Company will host a conference call at 5:00 p.m. (Eastern Time) that day to discuss the results. The toll-free dial-in for the conference call is (833) 470-1428 (U.S. & Canada), or click here for Global Dial-In Numbers. The conference...
-

Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent No. 12,558,367, which covers the methods of use of nicotinamide riboside (NR) and derivatives in intravenous and injectable formulations. Rob Fried, CEO of Niagen Bioscience, commented, “This p...
-

Momentous Launches Fiber+: The First Performance Fiber Designed to Support Gut Health, Metabolic Balance, and Whole-Body Recovery

PARK CITY, Utah--(BUSINESS WIRE)--Momentous, the leading human performance company focused on supplementation and nutrition, today announced the launch of Fiber+, the best-in-class performance-focused fiber supplement designed to go beyond digestion to support gut health, metabolic function, and whole-body health. Featuring a triple-action fiber formula, Fiber+ is an essential component for overall wellness, reimagining an outdated category with a product formulated to The Momentous Standard™....
-

GoodRx Expands Into Employer Market With Launch of “GoodRx Employer Direct”

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced the launch of GoodRx Employer Direct. The new offering enables employers to directly lower the cost of high-impact brand medications, including GLP-1s, by applying targeted subsidies to discounted cash prices from pharmaceutical manufacturers. Employers can also deploy branded versions of GoodRx’s condition-specific telemedicine solutions, integrating clinical...
-

Yukon Supports The Riverside Company’s Investment in Western Botanicals

MINNEAPOLIS--(BUSINESS WIRE)--Yukon Partners is pleased to announce it has partnered with The Riverside Company to support its investment in Western Botanicals....
-

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. “More than 2.5 million subscribers now rely on us for a healthcare experience that is both accessible and deeply personal – and we believe we’re well on our way to becoming the global leade...
-

Herbalife Plans to Refinance Senior Secured Debt

LOS ANGELES--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced plans to refinance its senior secured debt. The Company is targeting $1.55 billion of secured financing, which is expected to include a $425 million revolving credit facility, a $125 million Term Loan A, a $500 million Term Loan B and $500 million of other secured debt. The refinancing is also expected to extend the maturity profile of the senior secured debt....